Evidence map›Paper›PMID 22607061›Full record

ReviewAntioxidants & redox signaling2012

Cardiovascular redox and ox stress proteomics.

Vikas Kumar, Timothy Dean Calamaras, Dagmar Haeussler, Wilson Steven Colucci, Richard Alan Cohen, Mark Errol McComb, David Pimentel, Markus Michael Bachschmid

Abstract readReview
In one paragraph

Review in Antioxidants & redox signaling, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Redox RegulationAntioxidants & redox signaling · 2020
    Review
  4. Review
  5. Review
  6. Review
  7. Endothelial Cell Redox Regulation of Ischemic Angiogenesis.Journal of cardiovascular pharmacology · 2016
    Review
  8. Article
  9. Review
  10. Protein glutathionylation in cardiovascular diseases.International journal of molecular sciences · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vikas KumarVascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02118, USA.
Timothy Dean Calamaras
Dagmar Haeussler
Wilson Steven Colucci
Richard Alan Cohen
Mark Errol McComb
David Pimentel
Markus Michael Bachschmid

Funding

XI INTERNATIONAL SYMPOSIUM ON AMYLOIDOSISP41RR010888 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 1996 to 2011
$18.6M
SIRT1, Polyphenols, and Endothelial OxidantsP01HL068758 · NHLBI · BOSTON MEDICAL CENTER · PI WALSH, KENNETH · 2003 to 2013
$14.1M
Mass Spectrometry Resource for Biology and MedicineP41GM104603 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 2012 to 2017
$10.4M
Redox Regulation of SERCA by Nitric OxideR01HL031607 · NHLBI · BOSTON UNIVERSITY MEDICAL CENTER HOSP · PI COHEN, RICHARD A · 1985 to 2013
$4.8M
Training Program in Cardiovascular Biology: Pre-DoctoralT32HL007969 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2003 to 2019
$3.2M
Redox Regulation of p21ras in AngiogenesisR37HL104017 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COHEN, RICHARD A · 2010 to 2014
$2.2M
MALDI-TOF/TOF MS TO SUPPORT BIOMEDICAL RESEARCHS10OD010724 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 2012 to 2012
$590k
NHLBI PROTEOMICS INITIATIVE-N01HV28178N01HV028178 · HV · BOSTON UNIVERSITY MEDICAL CAMPUS · PI COSTELLO, CATHERINE E. · 2002 to 2006
–
NCRR NIH HHS P41 RR010888NHLBI NIH HHS HHSN268201000031CNHLBI NIH HHS P01 HL 068758NHLBI NIH HHS P01 HL068758NHLBI NIH HHS R01 HL031607NHLBI NIH HHS R01 HL31607NHLBI NIH HHS R37 HL104017NHLBI NIH HHS T32 HL007969NIGMS NIH HHS P41 GM104603NIH HHS S10 OD010724
6 · The paper itself

Abstract

significanceOxidative post-translational modifications (OPTMs) have been demonstrated as contributing to cardiovascular physiology and pathophysiology. These modifications have been identified using antibodies as well as advanced proteomic methods, and the functional importance of each is beginning to be understood using transgenic and gene deletion animal models. Given that OPTMs are involved in cardiovascular pathology, the use of these modifications as biomarkers and predictors of disease has significant therapeutic potential. Adequate understanding of the chemistry of the OPTMs is necessary to determine what may occur in vivo and which modifications would best serve as biomarkers. RECENT ADVANCES: By using mass spectrometry, advanced labeling techniques, and antibody identification, OPTMs have become accessible to a larger proportion of the scientific community. Advancements in instrumentation, database search algorithms, and processing speed have allowed MS to fully expand on the proteome of OPTMs. In addition, the role of enzymatically reversible OPTMs has been further clarified in preclinical models. CRITICAL ISSUES: The identification of OPTMs suffers from limitations in analytic detection based on the methodology, instrumentation, sample complexity, and bioinformatics. Currently, each type of OPTM requires a specific strategy for identification, and generalized approaches result in an incomplete assessment. FUTURE DIRECTIONS: Novel types of highly sensitive MS instrumentation that allow for improved separation and detection of modified proteins and peptides have been crucial in the discovery of OPTMs and biomarkers. To further advance the identification of relevant OPTMs in advanced search algorithms, standardized methods for sample processing and depository of MS data will be required.

Indexed as

Cardiovascular SystemOxidative StressProtein Processing, Post-TranslationalBiomarkersHumansMass SpectrometryOxidation-ReductionProteomeProteomicsSignal TransductionBiomarkersProteome

Identifiers

PMID22607061
PMCPMC3448941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.